| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 6,290,000 | 5,866,000 | 5,201,000 | 5,940,000 |
| Research and development | 17,232,000 | 19,021,000 | 14,345,000 | 48,809,000 |
| Restructuring charges | NaN | 0 | 0 | NaN |
| Cost of goods sold | 0 | 0 | 0 | 0 |
| Total operating expenses | 23,522,000 | 24,887,000 | 19,546,000 | 54,749,000 |
| Interest expense | NaN | 0* | 0 | 0 |
| Loss from operations | -23,522,000 | -24,887,000 | -19,546,000 | -54,749,000 |
| Gain on sale of business | 0 | 0 | -177,000 | 0 |
| Foreign exchange gain (loss) | NaN | 9,500* | 0 | -3,000 |
| Other income | NaN | 15,500* | 127,000 | 158,000 |
| Interest income | 1,328,000 | 1,611,000 | 1,850,000 | 1,979,000 |
| Total other income (expense), net | 1,328,000 | 1,636,000 | 1,800,000 | 2,134,000 |
| Loss (income) before income tax expense | -22,194,000 | -23,251,000* | NaN | NaN |
| Income tax expense (benefit) | 0 | 0* | NaN | NaN |
| Net (loss) income | -22,194,000 | -23,251,000 | -17,746,000 | -52,615,000 |
| Unrealized gain on investments, net of tax | -135,000 | -19,000 | 130,000 | 8,000 |
| Comprehensive (loss) income | -22,329,000 | -23,270,000 | -17,616,000 | -52,607,000 |
| Basic EPS | -0.32 | -0.376 | -0.26 | -0.76 |
| Diluted EPS | -0.32 | -0.376 | -0.26 | -0.76 |
| Basic Average Shares | 69,236,945 | 61,886,765* | 69,204,899 | 69,083,127 |
| Diluted Average Shares | 69,236,945 | 61,886,765* | 69,204,899 | 69,083,127 |
Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. (WHWK)